Vitrolife

AGM Information • Apr 27, 2023

Report from Annual General Meeting of Vitrolife AB (publ)

At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided:

• Resolution in accordance with the Board's proposed dividend of SEK 0.85 per share for the financial year 2022. Tuesday 2 May, 2023 was adopted as the record day.
• Re-election of Board members Henrik Blomquist, Lars Holmqvist, Vesa Koskinen, Pia Marions, Jón Sigurdsson and Karen Lykke Sørensen, in accordance with the election committee's proposal. Henrik Blomquist was elected Chairman of the Board.
• Remuneration to the members of the Board shall be totaling SEK 3,600,000, of which SEK 1,200,000 to the Chairman of the Board, SEK 400,000 to each of the other members of the Board, SEK 100,000 to the Chairman of the Audit Committee, SEK 100,000 to the Chairman of the Remuneration Committee and SEK 50,000 to the other members of these committees.
• The board's proposal for Amendment of the Articles of Association was approved.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
• Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
• Resolution to implement a share-based incentive program including issue of a maximum number of 229,500 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities.

Gothenburg, April 27, 2023 VITROLIFE AB (publ) The Board

Contact persons: Patrik Tolf, CFO, tel: +46 31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

___________________________________________________________________________________________________________________________________

Vitrolife Group's products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on NASDAQ Stockholm.

_____________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com

The information was submitted for publication, through the agency of the contact persons set out above, at 5.15 pm CET on April 27, 2023.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.